Identification of new lung cancer antigens and development of peptide vaccine

肺癌新抗原的鉴定及肽疫苗的研制

基本信息

  • 批准号:
    15590834
  • 负责人:
  • 金额:
    $ 2.24万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2003
  • 资助国家:
    日本
  • 起止时间:
    2003 至 2005
  • 项目状态:
    已结题

项目摘要

We had cloned 6 cancer antigen genes and those derived 10 epitope peptides recognized by cytotoxic T-lymphocytes in an HLA-restricted manner were identified. Their expression is not restricted in the lung cancers but also found in other adenocarcinomas and squamous cell carcinomas with relatively high level of expression. Therefore we conducted clinical trials, as the translational research, of the personalized peptide vaccines for patients with various cancers including cancers of the lung, colon, stomach, pancreas, prostate, and malignant brain tumors in total 178 cases using these epitope peptides with previously identified peptides. Local inflammation at the injected sites was frequently observed, however, systemic adverse events have not been detected except for fever(grade 2 of CTCAE ver 3)in some cases. These results indicated the safety of the personalized peptide vaccines. Anti-tumor effects of the vaccines were confirmed in patients with glioblastoma maltiforme. In the case of hormone refractory prostate cancers, combination therapy with the vaccines and low dose estramustin phosphate expressed clinical effects. Since some of the vaccine peptides elicited immediate hypersensitivity-like skin reactions in the prevaccination skin tests, precise mechanisms of the reaction was investigated in animal models. The peptide-induced skin reaction was elicited by degranulation of the mast cells with antibody-independent mechanisms. However, this degranulation of the mast cells was not induced systemic anaphylaxis, because of the rapid degradation of the vaccine peptides in the plasma. This phenomenon was unelated to the anti-cancer effect of the peptide vaccines. We also demonstrated the synergic effect of the peptide vaccination and intratumor injection of OK432 on anti-tumor effect and its mechanism through the efficient recruitment of systemically induced CTLs to the tumor sites.
我们已经克隆了6个癌抗原基因,并鉴定了这些基因衍生的10个表位肽,这些表位肽以HLA限制性方式被细胞毒性T淋巴细胞识别。它们的表达不仅限于肺癌,而且在其他腺癌和鳞状细胞癌中也有相对高水平的表达。因此,我们使用这些表位肽和先前鉴定的肽,在总共178个病例中进行了用于患有各种癌症(包括肺癌、结肠癌、胃癌、胰腺癌、前列腺癌和恶性脑肿瘤)的患者的个性化肽疫苗的临床试验,作为转化研究。经常观察到注射部位的局部炎症,然而,除了在某些病例中的发热(CTCAE版本3的2级)外,未检测到全身不良事件。这些结果表明了个体化肽疫苗的安全性。在恶性胶质母细胞瘤患者中证实了疫苗的抗肿瘤作用。在激素难治性前列腺癌的情况下,疫苗和低剂量磷酸雌莫司汀的联合治疗表现出临床效果。由于一些疫苗肽在接种前皮肤试验中引起了立即的过敏样皮肤反应,因此在动物模型中研究了反应的精确机制。肽诱导的皮肤反应是通过肥大细胞的脱颗粒引起的,具有抗体非依赖性机制。然而,由于疫苗肽在血浆中的快速降解,肥大细胞的这种脱粒不会诱导全身过敏反应。这种现象与肽疫苗的抗癌作用无关。我们还证实了肽疫苗接种和瘤内注射OK432对抗肿瘤效应的协同作用及其通过有效地将全身诱导的CTL募集到肿瘤部位的机制。

项目成果

期刊论文数量(137)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Antibody reactive to a hepatitis C virus (HCV)-derived peptide capable of inducing HLA-A2 rstricted cytotoxic T lymphocytes is detectable in the majority of HCV-infected individuals without HLA-A2 restriction.
在大多数无 HLA-A2 限制的 HCV 感染个体中,可检测到与丙型肝炎病毒 (HCV) 衍生肽反应的抗体,该肽能够诱导 HLA-A2 限制性细胞毒性 T 淋巴细胞。
  • DOI:
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    0
  • 作者:
    H.Shimizu;S.Maruyama;Y.Yuzawa;T.Kato;Y.Miki;Y.Morita;H.Maruyama;K.Egashira;S.Matsuo;Y.Takao
  • 通讯作者:
    Y.Takao
Antibody reactive to a hepatitis C virus(HCV)-derived peptide capable of inducing HLA-A2 restricted cytotoxic T lymphocytes is detectable in the majority of HCV-infected individuals without HLA-A2 restriction.
在大多数没有 HLA-A2 限制的 HCV 感染个体中,可检测到与能够诱导 HLA-A2 限制性细胞毒性 T 淋巴细胞的丙型肝炎病毒 (HCV) 衍生肽发生反应的抗体。
  • DOI:
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Takao Y;Yamada A;Yutani S;Sata M;Itoh K.
  • 通讯作者:
    Itoh K.
C型肝炎ウィルス由来ペプチドとインターフェロンとの併用療法
丙型肝炎病毒衍生肽和干扰素的联合治疗
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Nonmutated Self-Antigen-Derived Cancer Vaccine Peptides Elicit an lgE-Independent but Mast Cell-Dependent Immediate-Type Skin Reaction without Systemic Anaphylaxis.
非突变自身抗原衍生的癌症疫苗肽可引发不依赖于 lgE 但依赖于肥大细胞的立即型皮肤反应,而不会产生全身性过敏反应。
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Nishio S.;Hatano M.;Nagata M.;Horie S.;Koike T.;Tokuhisa T.;Mochizuki T.;Yamada A
  • 通讯作者:
    Yamada A
Depolmetization of actin Filament by cytochalasin E induces interleukin-8 production and up-regulates CD54 in the Hela epithelial cell line
细胞松弛素 E 对肌动蛋白丝的去极化可诱导 Hela 上皮细胞系中白细胞介素 8 的产生并上调 CD54
  • DOI:
  • 发表时间:
    2003
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Mine T;Sato Y;Noguchi M;Sasatomi T;Gouhara R;Tsuda N;Tanaka S;Shomura H;Katagiri K;Rikimaru T;Shichijo S;Kamura T;Hashimoto T;Shirouze K;Yamada A;Todo S;Itoh K;Yamana H.;N.Tsuda;Koga M;Kawamoto N;Tanaka S;Mine T;Ikewaki N
  • 通讯作者:
    Ikewaki N
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YAMADA Akira其他文献

Randomized phase II trials of personalized peptide vaccination in advanced cancers
晚期癌症个性化肽疫苗接种的随机 II 期试验
  • DOI:
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    0
  • 作者:
    ITO Kyogo;YUTANI Shigeru;SHICHIJO Sigeki;NOGUCHI Masanori;SASADA Tetsuro;YAMADA Akira;UEMURA Hirotsugu
  • 通讯作者:
    UEMURA Hirotsugu
Quantitative Evaluation of Liver Function with Gd-EOB-DTPA-enhanced MR Imaging
Gd-EOB-DTPA 增强 MR 成像对肝功能的定量评估
  • DOI:
    10.2463/jjmrm.2019-1692
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Sayaka Misaki;Satoshi Murata;Miyuki Shimoji;Takayasu Iwai;Andreas Michael Sihombing;Ken Aoki;Yutaka Takahashi;Yoshiyuki Watanabe;北野瑞稀;YAMADA Akira
  • 通讯作者:
    YAMADA Akira

YAMADA Akira的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YAMADA Akira', 18)}}的其他基金

Development of next generation transdermal vaccine for cancer treatment
开发用于癌症治疗的下一代透皮疫苗
  • 批准号:
    26430176
  • 财政年份:
    2014
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of Novel Silicon Nanowire Array Solar Cells
新型硅纳米线阵列太阳能电池的开发
  • 批准号:
    24656203
  • 财政年份:
    2012
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Evaluation of segmental liver reserve using functional imaging technique.
使用功能成像技术评估分段肝脏储备。
  • 批准号:
    23791405
  • 财政年份:
    2011
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Basic research for the development of multi-peptide cocktail vaccines for cancer
癌症多肽鸡尾酒疫苗开发的基础研究
  • 批准号:
    23501292
  • 财政年份:
    2011
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of high-efficiency Cu(InGa)Se2 thin-film solar cells fabricated by a nanoparticles based process
开发基于纳米颗粒的工艺制造的高效 Cu(InGa)Se2 薄膜太阳能电池
  • 批准号:
    22360006
  • 财政年份:
    2010
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Study on the regulation of actomyosin interactions by twithcin
twithcin调节肌动球蛋白相互作用的研究
  • 批准号:
    22570167
  • 财政年份:
    2010
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Visceral fat inspection method based on the ultrasound tomographic reconstruction of abdominal tissue sound speed image
基于腹部组织声速图像超声断层重建的内脏脂肪检查方法
  • 批准号:
    22560414
  • 财政年份:
    2010
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Fundamental study for development of a peptide vaccine against hepatitis C virus
丙型肝炎病毒肽疫苗开发基础研究
  • 批准号:
    20590799
  • 财政年份:
    2008
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Basic research for the development of peptide vaccination against Hepatitis C virus infection
丙型肝炎病毒感染肽疫苗开发的基础研究
  • 批准号:
    18590756
  • 财政年份:
    2006
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Ultrasound Transmission Beam Computed Tomography for the In-situ Sound Speed Quantitative Diagnostic Imaging of Abdominal Tissue
超声透射束计算机断层扫描用于腹部组织原位声速定量诊断成像
  • 批准号:
    17560367
  • 财政年份:
    2005
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Acquisition of basic data on cancer antigens for the development of vaccine therapies for lung cancer.
获取癌症抗原的基础数据,用于开发肺癌疫苗疗法。
  • 批准号:
    20K16380
  • 财政年份:
    2020
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The mechanism of activation/exhaustion of cytotoxic T cells by stratification of cancer antigens
通过癌症抗原分层激活/耗尽细胞毒性 T 细胞的机制
  • 批准号:
    19K16790
  • 财政年份:
    2019
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
HLA presentation mechanisms of long non-coding RNA-derived cancer antigens
长链非编码RNA衍生癌抗原的HLA呈递机制
  • 批准号:
    19H03490
  • 财政年份:
    2019
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Analysis of cancer antigens through novel HLA assay
通过新型 HLA 检测分析癌症抗原
  • 批准号:
    19K22551
  • 财政年份:
    2019
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A PHASE I TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A DNA PLASMID BASED VACCINE (WOKVAC) ENCODING EPITOPES DERIVED FROM THREE BREAST CANCER ANTIGENS (IGFBP-2, HER2, AND IGF-IR) IN PAT
PAT 中编码源自三种乳腺癌抗原(IGFBP-2、HER2 和 IGF-IR)表位的 DNA 质粒疫苗 (WOKVAC) 的安全性和免疫原性的 I 期试验
  • 批准号:
    9552662
  • 财政年份:
    2015
  • 资助金额:
    $ 2.24万
  • 项目类别:
A PHASE I TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A DNA PLASMID BASED VACCINE (WOKVAC) ENCODING EPITOPES DERIVED FROM THREE BREAST CANCER ANTIGENS (IGFBP-2, HER2, AND IGF-IR) IN PAT
PAT 中编码源自三种乳腺癌抗原(IGFBP-2、HER2 和 IGF-IR)表位的 DNA 质粒疫苗 (WOKVAC) 的安全性和免疫原性的 I 期试验
  • 批准号:
    9275893
  • 财政年份:
    2015
  • 资助金额:
    $ 2.24万
  • 项目类别:
Identification of novel cancer antigens for oral squamous cell carcinoma and research towards clinical application
口腔鳞状细胞癌新型癌抗原的鉴定及临床应用研究
  • 批准号:
    26463051
  • 财政年份:
    2014
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Engineering High-Affinity T Cell Receptors Against Cancer Antigens
设计针对癌症抗原的高亲和力 T 细胞受体
  • 批准号:
    8704723
  • 财政年份:
    2013
  • 资助金额:
    $ 2.24万
  • 项目类别:
Engineering High-Affinity T Cell Receptors Against Cancer Antigens
设计针对癌症抗原的高亲和力 T 细胞受体
  • 批准号:
    9318170
  • 财政年份:
    2013
  • 资助金额:
    $ 2.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了